Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
Research output: Contribution to journal › Article › peer-review
170Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study'. Together they form a unique fingerprint.